Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (STLN)

CUSIP: 68236X100

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
+3,814,679
Put/Call ratio
1.8%
SEC-reported price per share
$3.56
Number of holders
116
Value change
+$13,731,282
Number of buys
74
Open additional details 1 more signal available
Number of sells
43
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
101,268,340

Security key

68236X100

Report period

Q4 2025

Institutions

116

Top holders

10

Ownership snapshot

Top reported holders of STLN - Starling Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
M33 Growth I L.P.
Disclosed value leader
M33 Growth I L.P.
Comparable rows
2/15
Latest evidence
18 Nov 2025
3/4/5 13D/G 13F Lead comparable stake: 5.5% 13 rows are not safely comparable across share classes. 13D/G row: M33 Growth I L.P. Showing 1-6 of 15 holder rows.

Quick read

M33 Growth I L.P. leads the comparable SEC ownership view at 5.5%.

2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens M33 Growth I L.P.'s linked filing trail.
Comparable ownership Top 2
M33 Growth I L.P. 5.5%
Ravi Yang Sarin 4.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
M33 Growth I L.P.
3/4/5 13D/G
Director · M33 Growth I LP
5.5%
Reported 13D/G · 18 Nov 2025
$25,267,600
6,802,656 shares
mixed-class rows
— 18 Nov 2025
Ravi Yang Sarin
13D/G 3/4/5
Ravi Sarin · Director
4.7%
Reported 13D/G · 26 Mar 2025
$11,959,434
4,109,771 shares
$0 26 Mar 2025
James E. Flynn
3/4/5
Possible Members of 10% Group, 10%+ Owner
—
mixed-class rows
$448,270
7,887,160 shares
mixed-class rows
— 12 Nov 2021
Havencrest Healthcare Partners, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$115,652
252,626 shares
— 16 Aug 2024
DFP Sponsor LLC
3/4/5
Possible Members of 10% Group, 10%+ Owner
—
mixed-class rows
$5
3,177,583 shares
mixed-class rows
— 12 Nov 2021
Richy Agajanian
3/4/5
10%+ Owner
—
denominator unverified
—
296,075 shares
— 10 Jun 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
116
Shares
38,505,676
Rows available
116
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
107
Q4 2025 holders
116
Holder diff
9
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .